

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on December 26, 2002  
Date



Signature

Deborah A. Gunkel

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

The following forms are being transmitted herewith:  
Transmittal Letter, one page (in duplicate);  
Combined Notice of Appeal from the Primary Examiner  
to the Board of Patent Appeals and Interferences  
& Petition for Extension of Time Under 36 CFR 1.136(a)  
two pages (in duplicate);  
Power of Attorney by Assignee of Entire Interest  
(Revocation of Prior Powers), with Statement under  
37 CFR 3.373(b), four pages;  
Amendment and Response to Office Action, ten pages.

**TRANSMITTAL LETTER  
(General - Patent Pending)**Docket No.  
**CRI-3US**In Re Application Of: **Donald Mickle et al.**Serial No.  
**09/363,100**Filing Date  
**July 29, 1999**Examiner  
**Afremova, Vera**Group Art Unit  
**1651**Title: **MESENCHYMAL STEM CELL TRANSPLANTATION INTO DAMAGED MYOCARDIUM****TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:**

Transmitted herewith is:

**Amendment and Response to Office Action; Combined Notice of Appeal from the Primary Examiner to the Board of Patent Appeals and Interferences & Petition for Extension of Time under 37 CFR 1.136(a); Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) w/ih Statement under 37 CFR 3.73(b); and Certificate of Transmission under 37 CFR 1.8.**

in the above identified application.

No additional fee is required.


A check in the amount of \_\_\_\_\_ is attached.

The Commissioner is hereby authorized to charge and credit Deposit Account No. **07-1074** as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of **\$1,240.00**

Credit any overpayment.

Charge any additional fee required.

  
SignatureDated: **December 26, 2002**

**Madge R. Kanter**  
Reg. No. 35,211  
**GENZYME CORPORATION**  
One Kendall Square  
Cambridge, MA 02139  
Tel. (617) 761-8485  
Fax (617) 252-7977

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.6 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

*Signature of Person Mailing Correspondence**Typed or Printed Name of Person Mailing Correspondence*

CC:

*Docket Number CRI-3US*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Donald Mickle et al.  
Serial Number : 09/363,100  
Confirmation Number : 7723  
Examiner : Afremova, Vera  
Art Unit : 1651  
Filed : July 29, 1999  
For : MESENCHYMAL STEM CELL  
TRANSPLANTATION INTO DAMAGED  
MYOCARDIUM

Commissioner of Patents and Trademarks  
United States Patent and Trademark Office  
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 3.73(b)


Sir:

This Statement Under 37 C.F.R. § 3.73(b) accompanies a POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST, filed in the above-identified application concurrently herewith.

Evidence establishing that Genzyme Corporation is the assignee of the entire right, title and interest in the above-identified application, may be found in the Assignment recorded on December 16, 1999 at Reel 10462 and Frame 0885.

Evidence that the undersigned is authorized to act on behalf of Genzyme may be found in the attached SIGNATURE AUTHORITY.

Respectfully submitted,

  
Madge R. Kanter (Reg. No. 35,211)  
Attorney for Applicant  
Genzyme Corporation  
One Kendall Square  
Cambridge, Massachusetts 02139  
Tel. (617) 761-8485

Dated: December 26, 2002

**genzyme**

GENZYME CORPORATION  
ONE KENDALL SQUARE  
CAMBRIDGE, MA 02139-1562, U.S.A.  
617-252-7500  
FAX 617-252-7600

**SIGNATURE AUTHORITY**

I, Thomas J. DesRosier, Senior Vice President and General Counsel of Genzyme Corporation hereby appoint Madge R. Kanter, Richard Allison, Elizabeth Lassen and Bart G. Newland, all Managing Intellectual Property Counsel of Genzyme Corporation, with full power and authority to transact any and all business before the United States Patent and Trademark Office, and any foreign counterpart patent office, with the powers of a Corporate Officer of Genzyme Corporation.

Date: September 24, 2001



Thomas J. DesRosier, Esquire  
Senior Vice President and General Counsel  
GENZYME CORPORATION

**G hzyme Corporation**

One Kendall Square, 1400 Building, 4<sup>th</sup> Floor  
Cambridge, Massachusetts 02139 U.S.A.  
Telephone: (617) 252-7500  
Facsimile: (617) 252-7977

**LEGAL DEPARTMENT**

Maggie Kanter  
Direct Dial: (617) 761-8485  
maggie.kanter@genzyme.com

FAX RECEIVED

DEU 27 2002

GROUP 1600

**Facsimile**

To:	Vera Afremova	From:	Maggie Kanter
Fax:	(703) 308-4242	Pages:	22
Phone:	(703) 308-9351	Date:	12/26/2002
Re:	CRI-3US	CC:	

Application No.: 09/363,100  
Title: MESENCHYMAL STEM CELL  
TRANSPLANTATION INTO  
DAMAGED MYOCARDIUM

**OFFICIAL**

**NOTICE OF CONFIDENTIALITY**

This transmission is intended only for the addressee(s) listed above, and may contain information that is confidential or privileged. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If this message was received in error, please telephone us immediately.